GlassScriptPhysician profile
Kimberly Borris
NPI 1174528244
$2,958.00
in general payments reported to CMS, 2019-2025
27 companies · $334 in 2025
The $334 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $644 · 2022: $643 · 2023: $877 · 2024: $459 · 2025: $334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,670.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $636.83 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $546.04 | 2021-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $362.61 | 2021-2025 | |
| Pfizer INC. | $190.51 | 2021-2025 | |
| Lilly USA, LLC | $162.13 | 2021-2024 | Mounjaro, Trulicity, Zepbound |
| Glaxosmithkline, LLC. | $156.65 | 2023-2024 | Shingrix, Arexvy, Boostrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $111.32 | 2021-2024 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $89.07 | 2021-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $81.12 | 2021-2023 | Camzyos |
| Abbott Laboratories | $70.85 | 2022-2025 | Freestyle Libre 3 |
| Dynavax Technologies Corporation | $70.29 | 2024 | Heplisav-B |
| Bayer Healthcare Pharmaceuticals INC. | $62.31 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $57.76 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $53.12 | 2021-2025 | Airsupra, Farxiga |
| Astellas Pharma US INC | $31.27 | 2024 | Veozah |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $30.77 | 2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.13 | 2021-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $28.72 | 2021 | |
| Currax Pharmaceuticals LLC | $26.54 | 2021-2022 | |
| Daiichi Sankyo INC. | $25.63 | 2023 | Injectafer |
| Nevro Corp. | $23.63 | 2024 | Senza |
| Biohaven Pharmaceutical Holding Company LTD. | $22.86 | 2022 | |
| Philips North America LLC | $21.91 | 2024 | (Ck7) Extended Holter |
| Jazz Pharmaceuticals INC. | $21.37 | 2021 | |
| Heartflow, INC. | $16.43 | 2025 | |
| Xeris Pharmaceuticals, INC. | $15.46 | 2025 | Gvoke Hypopen |
| Medtronic, INC. | $12.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Borris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.